![](https://radiancebio.com/wp-content/uploads/2024/02/Brooks.jpeg)
Robert Brooks, JD: CEO
Robert Brooks, JD is the Founder and serves as Chief Executive Officer (CEO) of Radiance. Robert brings over 30 years of experience in the biotechnology, financial and legal industries. In 2022, he founded and serves as Chairman and CEO of Exocellular Diagnostics, a commercial stage company developing cancer diagnostics, with marketing approval in the European Union. In 2020, he founded and serves as Chairman and CEO of Alphageneron Pharmaceuticals, a clinical stage company focused on natural killer (NK) cell therapy. From 2016, he has been Managing Director of US Global Partners, LLC, investment firm. In 2015, he founded and serve as Chairman and CEO of Aurora Biopharma, a biotechnology company developing CAR T cell therapy for solid tumors. In 2012, he founded and served as Chairman and CEO of Medvax Technologies, a clinical stage biotechnology company focused on developing cancer vaccines. From 2000 to 2010, Mr. Brooks practiced corporate-securities law. From 1987 until 1999, he was employed in the financial and investment banking industry. He holds a Juris Doctorate (JD) degree from the University of Miami, Florida, and an undergraduate Bachelor of Science degree, Cum Laude, in Biology/Pre-Medicine.
He has held a Securities license. He serves on the Board of Directors of Medtherapy, Inc., a global cell and gene manufacturer.
![](https://radiancebio.com/wp-content/uploads/2023/10/Graham-Pockley-1-2.jpg)
A. Graham Pockley, PhD: Chief Scientific Officer
A. Graham Pockley serves as Chief Science Officer (CSO) of Radiance. He also serves as CSO of Alphageneron Pharmaceuticals, and ExoCellulular Diagnostics and CEO of multimmune GmbH, Munich, a clinical stage company developing NK cell therapy focused on membrane Hsp70. He is an Emeritus Professor of Immunobiology and former Director of the John van Geest Cancer Research Centre at Nottingham Trent University, UK. Between 2010 and 2021 he was the Founder and Chairman of Chromocyte, an online resource for flow cytometry and other antibody-related techniques, prior to its acquisition by Biocompare. Graham’s extensive academic career has focused on the immunobiology of disease, the development of new immunotherapeutic strategies for treating aggressive and ‘orphan’ cancers, new approaches for analysing and interpreting complex datasets and defining new biomarkers of disease presence,
Graham holds a BSc (Hons) in Biochemistry from the University of Sheffield, UK and a PhD in Immunology from Sheffield Hallam University, also in Sheffield, UK.